Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00787605 · ClinicalTrials.gov registry record · Phase 4
Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 860
- Enrollment target
NCT00787605: Completed Phase 4 study, sponsored by Novartis.
NCT00787605 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 860 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (66% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00787605, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 860 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the blood pressure lowering effect and safety of aliskiren in combination with Hydrochlorothiazide (HCTZ) given to diabetic patients with stage 2 systolic hypertension (mean sitting systolic blood pressure (msSBP) ≥ 160 mm Hg and \< 200 mm Hg).
Interventions
- DRUG Amlodipine
- DRUG Aliskiren
- DRUG Hydrochlorothiazide (HCTZ)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 860 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
What the finished NCT00787605 record still lists
NCT00787605 is an interventional study that assigns participants to a tested intervention. The registered 860 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (66% higher).
The record links to 0 conditions, and to 3 interventions - of which Amlodipine is the first listed.
NCT00787605 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00787605 about?
NCT00787605 is a clinical study titled "Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus". The purpose of the study is to evaluate the blood pressure lowering effect and safety of aliskiren in combination with Hydrochlorothiazide (HCTZ) given to diabetic patients with stage 2 systolic hypertension (mean sitting systolic blood pressure (msSBP) ≥ 160 mm Hg and \< 200 mm Hg).
What is the current status of trial NCT00787605?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 860 participants. The study started on 2008-11. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00787605?
The interventions under investigation include: Amlodipine (DRUG), Aliskiren (DRUG), Hydrochlorothiazide (HCTZ) (DRUG).
Who is sponsoring clinical trial NCT00787605?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00787605's enrollment target sits among peer trials
860 88th of 2000 higher than 1,913 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04541381 · 860 participants · NA
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
- NCT05211895 · 860 participants · Phase 3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
- NCT06161025 · 860 participants · Phase 2
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- NCT06541574 · 860 participants · Phase 2
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia